A 60-Year-Old Man Presents With Plantar Hyperkeratosis & Erythema

Poll

A 60-year-old man presents with localized tender plaques of hyperkeratosis and a surrounding erythematous halo on the weight-bearing plantar aspect of his feet after beginning cancer treatment. Which medication is responsible for this cutaneous presentation and what is the name of this reaction?

A 60-year-old man presents with localized tender plaques of hyperkeratosis and a surrounding erythematous halo on the weight-bearing plantar aspect of his feet after beginning cancer treatment.

What is your diagnosis?

A. Capecitabine, hand-foot skin reaction
B. Capecitabine, hand-foot syndrome
C. Regorafenib, hand-foot syndrome
D. Regorafenib, hand-foot skin reaction
Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content
Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma can now receive treatment with pirtobrutinib.

FDA Gives Accelerated Approval to Pirtobrutinib in CLL/SLL

December 1st 2023
Article

Patients with chronic lymphocytic leukemia and small lymphocytic lymphoma can now receive treatment with pirtobrutinib.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

The FDA accepts the supplemental biologics license application for enfortumab vedotin-ejfv and pembrolizumab in patients with urothelial cancer following supporting data from the phase 3 KEYNOTE-A39 trial.

FDA Grants Priority Review for Pembrolizumab Combo in Bladder Cancer

December 1st 2023
Article

The FDA accepts the supplemental biologics license application for enfortumab vedotin-ejfv and pembrolizumab in patients with urothelial cancer following supporting data from the phase 3 KEYNOTE-A39 trial.

New treatment updates could help find more patient subtypes to target and treat in the world of CRC.

Multidisciplinary Care and New Treatment Options in CRC

November 20th 2023
Podcast

New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

CAR T-cell Therapy Remains Preferred Options for Relapsed/Refractory Multiple Myeloma

December 1st 2023
Article

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD.

Durvalumab/Tremelimumab/Surgery Appears Safe in Renal Cell Carcinoma

November 30th 2023
Article

Surgery following treatment with checkpoint inhibitors yields no surgical complications in a cohort of patients with advanced renal cell carcinoma, according to Jason Scovell, MD, PhD.